Ionis Pharmaceuticals has entered into a license agreement with Recordati, granting the company exclusive rights to develop and commercialize zilganersen in all countries outside the U.S. The deal includes an upfront payment of $30 million, with additional milestone payments and tiered royalties reaching up to the mid-20% range on annual net sales. Ionis retains sole commercial responsibility for zilganersen in the U.S. and will continue to lead global development efforts.

Recordati will handle regulatory filings and commercialization outside the U.S., including support for early access pathways based on local regulations. Brett P. Monia, Ph.D., chief executive officer of Ionis, highlighted Recordati's expertise in rare diseases and global commercialization as key factors in the partnership. The collaboration aims to address the high unmet need for Alexander disease (AxD), a rare and often fatal neurodegenerative disorder.

Zilganersen is an investigational RNA-targeted medicine designed to inhibit excess glial fibrillary acidic protein (GFAP) production caused by variants in the GFAP gene. The U.S. Food and Drug Administration (FDA) has granted it Breakthrough Therapy, Orphan Drug, and Rare Pediatric Disease designations. The European Medicines Agency (EMA) has also granted Orphan Drug designation. Ionis plans to independently launch zilganersen in the U.S., pending FDA approval, marking its first independent commercial launch in neurology.

The pivotal study for zilganersen met its primary endpoint in individuals aged 5 and older, demonstrating statistically significant and clinically meaningful stabilization of gait speed at Week 61. Secondary and exploratory endpoints consistently favored the treatment. Zilganersen showed a favorable safety profile, with most adverse events mild or moderate. Serious treatment-emergent adverse events occurred less frequently in the zilganersen group compared to the control group.

Key Agreement Terms

Rob Koremans, Chief Executive Officer of Recordati, emphasized the addition of zilganersen to the company's Rare Diseases portfolio. He noted the therapy's potential to address significant unmet medical need for AxD patients. The partnership leverages Ionis' innovation and Recordati's global rare disease capabilities to maximize the treatment's reach.

Leerink Partners analyst Mani Foroohar has maintained an Outperform rating on Ionis Pharmaceuticals (NASDAQ: IONS) while raising the price target to $122 from $114. The adjustment reflects a revised outlook on the company's valuation and market performance.

Rating and Price Target Details

The research note highlights the firm's continued confidence in Ionis Pharmaceuticals despite the shift in price targets. The new target of $122 represents an increase over the prior estimate of $114.

The updated guidance provides investors with a new benchmark for the stock's potential trajectory.